Although the serum levels of angiotensin II and angiotensin1–7 were not measured in our study population, our results may indirectly support the hypothesis of an effect of RAS modifiers on angiotensin II accumulation observed during the acute phase of COVID-19. This evidence concerns the gene AGT and COVID-19.